These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
150 related articles for article (PubMed ID: 11329854)
1. Peroxisome proliferator-activated receptor (PPAR) gamma agonists for diabetes. Moller DE; Greene DA Adv Protein Chem; 2001; 56():181-212. PubMed ID: 11329854 [No Abstract] [Full Text] [Related]
2. Peroxisome proliferator-activated receptor alpha/gamma dual agonists for the treatment of type 2 diabetes. Henke BR J Med Chem; 2004 Aug; 47(17):4118-27. PubMed ID: 15293980 [No Abstract] [Full Text] [Related]
3. New pharmacologic agents for diabetes. Bailey CJ Curr Diab Rep; 2001 Oct; 1(2):119-26. PubMed ID: 12643107 [TBL] [Abstract][Full Text] [Related]
4. [Evaluation of a thiazolidinedione compound as a new antidiabetic drug]. Toyota T Nihon Rinsho; 2001 Nov; 59(11):2211-8. PubMed ID: 11712410 [TBL] [Abstract][Full Text] [Related]
5. Novel peroxisome proliferator-activated receptor ligands for Type 2 diabetes and the metabolic syndrome. Miller AR; Etgen GJ Expert Opin Investig Drugs; 2003 Sep; 12(9):1489-500. PubMed ID: 12943493 [TBL] [Abstract][Full Text] [Related]
6. Design and synthesis of alpha-aryloxy-alpha-methylhydrocinnamic acids: a novel class of dual peroxisome proliferator-activated receptor alpha/gamma agonists. Xu Y; Rito CJ; Etgen GJ; Ardecky RJ; Bean JS; Bensch WR; Bosley JR; Broderick CL; Brooks DA; Dominianni SJ; Hahn PJ; Liu S; Mais DE; Montrose-Rafizadeh C; Ogilvie KM; Oldham BA; Peters M; Rungta DK; Shuker AJ; Stephenson GA; Tripp AE; Wilson SB; Winneroski LL; Zink R; Kauffman RF; McCarthy JR J Med Chem; 2004 May; 47(10):2422-5. PubMed ID: 15115385 [TBL] [Abstract][Full Text] [Related]
7. PPAR-gamma agonists: therapeutic role in diabetes, inflammation and cancer. Murphy GJ; Holder JC Trends Pharmacol Sci; 2000 Dec; 21(12):469-74. PubMed ID: 11121836 [TBL] [Abstract][Full Text] [Related]
8. A tailored therapy for the metabolic syndrome: the dual peroxisome proliferator-activated receptor-alpha/gamma agonist LY465608 ameliorates insulin resistance and diabetic hyperglycemia while improving cardiovascular risk factors in preclinical models. Etgen GJ; Oldham BA; Johnson WT; Broderick CL; Montrose CR; Brozinick JT; Misener EA; Bean JS; Bensch WR; Brooks DA; Shuker AJ; Rito CJ; McCarthy JR; Ardecky RJ; Tyhonas JS; Dana SL; Bilakovics JM; Paterniti JR; Ogilvie KM; Liu S; Kauffman RF Diabetes; 2002 Apr; 51(4):1083-7. PubMed ID: 11916929 [TBL] [Abstract][Full Text] [Related]
9. Peroxisome proliferator-activated receptor-gamma: therapeutic target for diseases beyond diabetes: quo vadis? Pershadsingh HA Expert Opin Investig Drugs; 2004 Mar; 13(3):215-28. PubMed ID: 15013941 [TBL] [Abstract][Full Text] [Related]
11. Novel "second-generation" approaches for the control of type 2 diabetes. Rotella DP J Med Chem; 2004 Aug; 47(17):4111-2. PubMed ID: 15293978 [No Abstract] [Full Text] [Related]
13. PPARgamma agonists in the treatment of type II diabetes: is increased fatness commensurate with long-term efficacy? Larsen TM; Toubro S; Astrup A Int J Obes Relat Metab Disord; 2003 Feb; 27(2):147-61. PubMed ID: 12586994 [TBL] [Abstract][Full Text] [Related]
14. A new insight into the treatment of diabetes by means of pan PPAR agonists. Chandra A; Kaur P; Sahu SK; Mittal A Chem Biol Drug Des; 2022 Dec; 100(6):947-967. PubMed ID: 34990085 [TBL] [Abstract][Full Text] [Related]
15. The structure-activity relationship between peroxisome proliferator-activated receptor gamma agonism and the antihyperglycemic activity of thiazolidinediones. Willson TM; Cobb JE; Cowan DJ; Wiethe RW; Correa ID; Prakash SR; Beck KD; Moore LB; Kliewer SA; Lehmann JM J Med Chem; 1996 Feb; 39(3):665-8. PubMed ID: 8576907 [No Abstract] [Full Text] [Related]